TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis
Biochemical Society Transactions · 29.07.2026 · 54 (7) · 901-913
DOI: 10.1042/bst20260896 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 01.07.2026. Verfasst von Eleni Christoforidou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, School of Life Sciences, University of Sussex, Brighton, U.K. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, DNA-Binding Proteins, TDP-43 Proteinopathies. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Motor Neurone Disease Association (MNDA), LifeArc.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is the most common form of adult-onset motor neuron disease, characterised by the degeneration of upper and lower motor neurons. The cytoplasmic aggregation of TDP-43 (TAR DNA-binding protein 43), an RNA-binding protein, is considered a hallmark of ALS pathology, found in nearly all postmortem cases of ALS. TDP-43 is normally primarily nuclear, where it has a widespread role in gene regulation. Mutations, extrinsic stressors, and alterations in RNA homeostasis in ALS lead to nuclear depletion of TDP-43 and the formation of cytosolic TDP-43 aggregates. This causes multiple downstream effects on neuronal function and degeneration as well as gene expression. TDP-43 is a promising target as a biomarker, as it is found to be elevated in the biofluids of ALS patients, and its cytoplasmic aggregation can also be observed in peripheral tissues; however, methodological variability and technical limitations currently preclude the establishment of TDP-43 as a standalone biomarker. There are also promising therapeutic strategies in development targeting TDP-43 pathology, but a critical challenge that remains is achieving a balance between eliminating toxic aggregates and preserving the essential functions of TDP-43. In summary, with further research, considering TDP-43 pathology in ALS gives hope for finding future novel diagnostics and therapeutics for ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, School of Life Sciences, University of Sussex, Brighton, U.K.
ORCID-Profile: Eleni Christoforidou, Martha McLaughlin, Majid Hafezparast
Förderung
- Motor Neurone Disease Association (MNDA)
- LifeArc
Zitieren
APA
Christoforidou, E., McFagan, E., McLaughlin, M., & Hafezparast, M. (2026). TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis. Biochemical Society Transactions, 54(7), 901-913. https://doi.org/10.1042/bst20260896
Vancouver
Christoforidou E, McFagan E, McLaughlin M, Hafezparast M. TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis. Biochemical Society Transactions. 2026;54(7):901-913. doi:10.1042/bst20260896
BibTeX
@article{Christoforidou2026,
author = {Christoforidou, Eleni and McFagan, Emily and McLaughlin, Martha and Hafezparast, Majid},
title = {TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis},
journal = {Biochemical Society Transactions},
year = {2026},
volume = {54},
number = {7},
pages = {901--913},
doi = {10.1042/bst20260896}
}
EUVIMED